Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
- Associated Therapies
- -
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 111
- Registration Number
- NCT02342704
- Locations
- 🇬🇧
Research Site, Glasgow, Strathclyde, United Kingdom
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Conditions
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 15
- Registration Number
- NCT02325440
- Locations
- 🇩🇪
Universitaetsklinikum Muenster, Department of Neurology, Muenster, Germany
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT02241785
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT02176031
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Natalizumab Subcutaneous Immunogenicity and Safety Study
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2
- Registration Number
- NCT02142192
- Locations
- 🇧🇪
Research Site, Liege, Belgium
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT02137109
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- John Levine
- Target Recruit Count
- 76
- Registration Number
- NCT02133924
- Locations
- 🇺🇸
Northwestern, Chicago, Illinois, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Biogen
- Target Recruit Count
- 161
- Registration Number
- NCT01955707
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 889
- Registration Number
- NCT01416181
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 97
- Registration Number
- NCT01416155
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.